Royalty Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +47.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 44.7x | Better than 11% |
| Forward P/E | 40.7x | Better than 10% |
| Price / Sales | 11.6x | Better than 9% |
| P/E vs own 5-yr range | 84th pctl | Better than 22% |
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 2.1% | Better than 35% |
| Net income CAGR (3Y) | 162.1% | Better than 98% |
| Free cash flow CAGR (3Y) | 5.1% | Better than 46% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | 65.6% | Better than 99% |
| Net margin | 32.4% | Better than 92% |
| Return on equity | 11.5% | Better than 57% |
| Return on invested capital | 7.0% | Better than 55% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 12.0% | Better than 92% |
| 6-month return | 26.5% | Better than 88% |
| 12-month return (ex latest month) | 66.3% | Better than 89% |
| Distance below 52-week high | 2.4% | Better than 98% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.4x | Better than 64% |
| Debt to assets | 45.6% | Better than 19% |
| Interest coverage | 5.3x | Better than 58% |
| Free cash flow / net income | 323.0% | Better than 87% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 6.2% | Better than 9% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 67.72
- Open
- 68.17
- Day range
- 67.95 - 68.83
- Avg price
- 68.41
- Volume
- 3.53M
- Turnover
- 241.62M
- Turnover ratei
- 0.85%
- Volume ratioi
- 1.15
- Amplitudei
- 1.30%
- 52-week rangei
- 36.68 - 70.13
Valuation
- P/Ei
- 38.46
- P/E (TTM)i
- 44.74
- P/Bi
- 4.46
- EPSi
- 1.78
- Book value / shi
- 15.36
- Net profit
- 792.57M
- Net assets
- 6.84B
Share structure
- Market cap
- 30.48B
- Float capi
- 28.44B
- Shares out
- 445.27M
- Float sharesi
- 415.52M
Dividend & listing
- Div yield (TTM)i
- 1.35%
- Dividend (TTM)
- 0.93
- Listing date
- 2020-06-16
2.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-54.18M net over the window
Short interest
- Shares short
- 13.08M
- % of floati
- 2.94%
- Days to coveri
- 3.97
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Royalty Pharma (RPRX)?
Royalty Pharma last traded at 68.45. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Royalty Pharma's market cap?
About 30.48B.
What is the P/E ratio of Royalty Pharma?
The trailing twelve-month P/E is 44.74, above its own 5-year average of 42.10 — toward the top of its historical range (83.51% percentile). See the Valuation tab for the full history.
Does Royalty Pharma pay a dividend?
Yes. The trailing dividend yield is 1.35%. The 2025 payout was up 4.8% from 2024. See the Dividends tab for the full payment history.
Is Royalty Pharma a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 72.67, which implies 6.2% upside from the current price. This is not investment advice.
What is Royalty Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Royalty Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.
Royalty Pharma discussion 0 comments